Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.770
-0.150 (-7.81%)
May 15, 2026, 4:00 PM EDT - Market closed
Acrivon Therapeutics Employees
As of December 31, 2025, Acrivon Therapeutics had 76 total employees, including 74 full-time and 2 part-time employees. The number of employees decreased by 2 or -2.56% compared to the previous year.
Employees
76
Change (1Y)
-2
Growth (1Y)
-2.56%
Revenue / Employee
n/a
Profits / Employee
-$1,016,671
Market Cap
75.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 76 | -2 | -2.56% | 74 | 2 |
| Dec 31, 2024 | 78 | 17 | 27.87% | 75 | 3 |
| Dec 31, 2023 | 61 | 17 | 38.64% | 58 | 3 |
| Sep 30, 2023 | 59 | 17 | 40.48% | 56 | 3 |
| Jun 30, 2023 | 53 | 17 | 47.22% | 50 | 3 |
| Mar 31, 2023 | 48 | 12 | 33.33% | 45 | 3 |
| Dec 31, 2022 | 44 | - | - | 41 | 3 |
| Sep 30, 2022 | 42 | - | - | 39 | 3 |
| Jun 30, 2022 | 36 | - | - | 35 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| XBiotech | 85 |
| Fortress Biotech | 78 |
| Seres Therapeutics | 66 |
| Cue Biopharma | 29 |
| PDS Biotechnology | 24 |
| Gain Therapeutics | 21 |
| Rallybio | 14 |
ACRV News
- 2 days ago - Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c) - TheFly
- 4 days ago - Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts - GlobeNewsWire
- 4 weeks ago - Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c) - TheFly
- 2 months ago - Acrivon Therapeutics sees cash runway into 2Q27 - TheFly
- 2 months ago - Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors - GlobeNewsWire